R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.

Arts, J; Angibaud, P; Mariën, A; Floren, W; Janssens, B; King, P; van Dun, J; Janssen, L; Geerts, T; Tuman, R W; Johnson, D L; Andries, L; Jung, M; Janicot, M; van Emelen, K

Arts, J; Angibaud, P; Mariën, A; Floren, W; Janssens, B; King, P; van Dun, J; Janssen, L; Geerts, T; Tuman, R W; Johnson, D L; Andries, L; Jung, M; Janicot, M; van Emelen, K.

Affiliation

Arts J; Oncology Research, Johnson & Johnson Pharmaceutical Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium. jarts@prdbe.jnj.com

Br J Cancer ; 97(10): 1344-53, 2007 Nov 19.

Article in En | MEDLINE | ID: mdl-18000499

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfones / Enzyme Inhibitors / Histone Deacetylase Inhibitors / Hydroxamic Acids / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Language: En Journal: Br J Cancer Year: 2007 Document type: Article Affiliation country: Bélgica Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google